These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22054301)

  • 21. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
    Shubrook JH; Colucci RA; Schwartz FL
    Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of saxagliptin stability using a new approach based on Partial Least Squares and Design of Experiments.
    Jordan N; Zakrajšek J; Bohanec S; Roškar R; Grabnar I
    Pharm Dev Technol; 2020 Dec; 25(10):1260-1270. PubMed ID: 32880215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
    Patel CG; Zhang J; Li L; Gooding L; Croop R; Li T; Boulton DW
    J Clin Pharmacol; 2010 Oct; 50(10):1211-6. PubMed ID: 20150522
    [No Abstract]   [Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.
    Mason RP; Jacob RF; Kubant R; Ciszewski A; Corbalan JJ; Malinski T
    J Cardiovasc Pharmacol; 2012 Nov; 60(5):467-73. PubMed ID: 22932707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
    Xie H; Zeng L; Zeng S; Lu X; Zhang G; Zhao X; Cheng N; Tu Z; Li Z; Xu H; Yang L; Zhang X; Huang M; Zhao J; Hu W
    Eur J Med Chem; 2012 Jun; 52():205-12. PubMed ID: 22475866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran.
    Hatanaka T; Inoue Y; Arima J; Kumagai Y; Usuki H; Kawakami K; Kimura M; Mukaihara T
    Food Chem; 2012 Sep; 134(2):797-802. PubMed ID: 23107693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system.
    Hikida A; Ito K; Motoyama T; Kato R; Kawarasaki Y
    Biochem Biophys Res Commun; 2013 Jan; 430(4):1217-22. PubMed ID: 23268343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
    Simpkins LM; Bolton S; Pi Z; Sutton JC; Kwon C; Zhao G; Magnin DR; Augeri DJ; Gungor T; Rotella DP; Sun Z; Liu Y; Slusarchyk WS; Marcinkeviciene J; Robertson JG; Wang A; Robl JA; Atwal KS; Zahler RL; Parker RA; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6476-80. PubMed ID: 17937986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
    Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
    Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
    Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
    Frederich R; Alexander JH; Fiedorek FT; Donovan M; Berglind N; Harris S; Chen R; Wolf R; Mahaffey KW
    Postgrad Med; 2010 May; 122(3):16-27. PubMed ID: 20463410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.